Overview of Hemohes

The following summary provides essential facts regarding the identity, composition, and general class of the medicinal product Hemohes.

Property	Description
Active ingredient	Hetastarch (Hydroxyethyl Starch, HES)
Form	Solution for infusion (Intravenous)
Pharmacological class	Plasma Volume Expander, Colloid solution
Common purpose	Acute volume replacement, Circulatory stabilization
Origin	Synthetic derivative of natural starch (polysaccharide)

The Identity of Hemohes: What Type of Medicine Is It?

Hemohes is a recognized medicinal product whose primary function is to serve as a Plasma Volume Expander, which places it within the high-level pharmacological class of Colloid solutions. Its active component, the generic name for which is Hetastarch, is formulated for the immediate replacement of lost fluid volume within the circulatory system. This substance is delivered as a sterile Solution for infusion, suitable exclusively for intravenous (IV) administration, and is defined as a single active ingredient preparation. Hetastarch is widely recognized for its use in volume resuscitation to manage acute blood loss.

Hetastarch Composition: Synthetic Origin and Functional Base

The functional essence of Hemohes is its ingredient, Hetastarch, which is a synthetic polysaccharide derivative engineered from natural starch. This high molecular weight component is dissolved in a basic, aqueous electrolyte solution, which acts as the vehicle for drug delivery and ensures its isotonicity. The synthetic modification of this starch derivative is essential, as its specific molecular structure enables a sustained presence in the circulation, maintaining its osmotic activity.

General Purpose: Why is a Colloid Expander Used?

The main purpose of Hemohes is acute volume replacement, aimed at the immediate restoration of circulatory stability following states of significant fluid loss, such as those encountered in trauma or surgical procedures. By providing sustained plasma volume expansion, the medication helps restore and maintain essential blood pressure and adequate blood flow. This general benefit of stabilizing circulatory stability is achieved through the compound’s specialized oncotic activity, allowing it to effectively retain the necessary volume of fluid in the blood vessels when a patient requires rapid volume support. Its role as a reliable volume support agent is clinically recognized in emergency medical contexts.

What side effects are possible with Hemohes?

Possible Side Effects and Safety Information

The official safety information for Hemohes (Hetastarch) classifies adverse reactions based on their frequency and the body system affected, reflecting the standards set by governmental regulatory agencies.

Frequency-Classified Reactions and System Involvement

Adverse effects are grouped by their frequency, with the most significant risks impacting the body's fluid balance, blood, and kidneys.

Classification	Example Reactions	Involved System
Common	Pruritus (itching), Hemodilution	Skin and Subcutaneous Tissue; Blood and Lymphatic System
Rare	Anaphylactoid reactions, Blood coagulation disturbances (high dose)	Immune System; Blood and Lymphatic System
Not Known	Acute Kidney Injury, Hepatic Injury	Renal and Urinary Disorders; Hepatobiliary Disorders

Serious Adverse Reactions and Restrictions

Regulatory documentation highlights serious adverse risks associated with Hetastarch products, including an increased risk of mortality and the need for Renal Replacement Therapy (dialysis) in certain patient groups. Severe coagulopathy (excessive bleeding) is also a documented concern.

Use of Hemohes is contraindicated and formally restricted in several conditions, including severe congestive heart failure, pre-existing severe renal impairment, and critically ill adult patients, such as those with sepsis. Additionally, use is restricted in patients with severe hypernatremia or severe hyperchloremia, and those with known intracranial bleeding or pre-existing severe coagulation disorders.

Some safety patterns are related to exposure: pruritus may be protracted (long-lasting), and the risk of coagulopathy increases with higher doses or repeat administrations. Renal function must be monitored for an extended period following administration.

Overdose and Emergency Response

Overdose and When to Seek Help — Official Regulatory Information

Hemohes is a brand name for a hydroxyethyl starch (HES) solution. Official regulatory warnings address the serious risks associated with the administration of HES products, particularly in vulnerable populations, which constitute an overdose-like scenario or exposure risk.

Documented Overdose Presentations and Symptoms

The primary serious manifestations documented in regulatory warnings for HES products include an increased risk of mortality and Acute Kidney Injury (AKI), which may necessitate Renal Replacement Therapy (RRT) (dialysis). Additionally, a risk of excess bleeding has been noted.

Population-Specific Overdose Risks

Increased risk of mortality and AKI is explicitly cited in certain patient groups: those with severe sepsis, surgical patients, and blunt trauma patients. These populations face a higher exposure-related risk for severe adverse outcomes.

Required Emergency Actions

The regulatory guidance emphasizes that HES products should not be used unless adequate alternative treatment is unavailable due to the serious risks. Treatment, when initiated, must be stopped as soon as appropriate haemodynamic goals have been achieved to limit exposure. The potential for fatal outcomes and the need for organ support (RRT) dictate that any manifestation of kidney problems, excess bleeding, or unexpected deterioration requires immediate medical attention.

Therapeutic Uses of Hemohes

What Hemohes Treats: Main Uses and Benefits

The primary therapeutic domain of Hemohes is applied in clinical settings that involve acute or unstable symptom patterns requiring necessary fluid replacement. Its main use is in the treatment of hypovolemia, when plasma volume expansion is desired, which addresses symptoms related to systemic imbalance (low blood volume).

The medication is commonly used across conditions presenting with acute episodes of significant fluid loss, such as those caused by trauma or major surgery. It plays a role in managing volume expansion to address the symptoms of circulatory instability, such as abnormally low blood pressure, which helps maintain a sense of stability when symptoms are more noticeable. The therapeutic indications covered include the management of volume deficits due to acute blood loss, treatment of hemorrhagic shock, and peri-operative volume support.

“The primary benefit is supporting the restoration of essential blood volume and helping to ease the critical symptom load during emergency care.”

In specialized contexts, the active ingredient also may assist with the collection of white blood cells (granulocytes) during leukapheresis procedures. It is relevant when supportive symptom management is appropriate in trauma resuscitation and surgical settings.

Quick Fact: Relief for Circulatory Instability Hemohes is applied in addressing symptoms that interfere with daily comfort and supports the patient during difficult episodes.

Regulatory References

NIH DailyMed: 6% Hetastarch in 0.9% Sodium Chloride Injection

Eligibility and Restrictions for Use

Official Eligibility Profile: Who Can and Cannot Use Hemohes (Hetastarch)

Regulatory documents from health authorities like the FDA and EMA establish strict eligibility criteria for Hetastarch (the active ingredient in Hemohes), severely limiting its use.

Contraindicated Populations (Absolute Ban)

Hetastarch must not be used in a wide range of patients. This includes all critically ill adult patients, particularly those with sepsis, due to documented increased risks. It is also contraindicated in patients with pre-existing coagulation or bleeding disorders, severe liver disease, and renal impairment or failure, especially in those receiving dialysis.

Age and Physiological Restrictions

Population Group	Regulatory Status
Pediatric Patients (Children)	Not recommended; safety and effectiveness have not been established due to insufficient data.
Adult Patients	The established population for use, provided no contraindications exist.
Pregnancy	Not recommended (FDA Pregnancy Category C).

Additional contraindications include patients with volume overload (e.g., severe heart failure), burn injury, and those with intracranial or cerebral bleeding.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Unlike many medications that have classic drug-drug interactions (e.g., those affecting enzymes like CYP450 or drug transporters), the official regulatory information for Hemohes (a Hydroxyethyl Starch or HES solution) is dominated by safety constraints related to patient condition rather than specific pharmaceutical interactions.

Officially documented drug-drug interactions with specific medicines or drug classes are not explicitly listed in the regulatory documents' interaction sections. However, the product's use requires careful consideration of its effects on the patient's biological systems, which is a key interaction context:

Coagulation: HES products may interfere with the coagulation system and are associated with an increased risk of excess bleeding. This effect warrants close monitoring of coagulation parameters in all patients.
Excretion: HES is primarily excreted via the kidneys. Its use requires caution in patients with pre-existing renal dysfunction and should be discontinued at the first sign of renal injury to prevent accumulation and further harm.

Regulatory Restrictions

The most significant constraints are regulatory restrictions based on patient population, functioning as high-level contraindicated interactions with patient conditions:

Do Not Combine with Condition: Hemohes is contraindicated for use in critically ill patients, patients with sepsis, and patients with pre-existing kidney impairment due to an established risk of increased mortality and severe kidney injury, including the need for renal replacement therapy. Furthermore, regulatory bodies in the European Union have recommended the suspension of marketing authorisations for all HES solutions for infusion due to these serious risks.

Mechanism of Action

MECHANISM OF ACTION

Hydroxyethyl Starch: Oncotic Action

Hydroxyethyl starch (HES) is a synthetic colloid comprised of highly branched glucose polymers. Due to their large molecular weight, HES molecules are predominantly retained within the intravascular space. The presence of these molecules enhances the oncotic pressure of the plasma compartment, which drives a net shift of water from the interstitial space into the circulation, leading to an increase in plasma volume.

Pharmacokinetic Modulation

The molecular weight distribution and degree of substitution of the HES polymers are physical properties that influence their plasma retention and rate of clearance. This structure provides the compound with an extended plasma half-life, which is the mechanism for maintaining the induced intravascular volume expansion over time.

Downstream Physiological Effect

The intravascular volume increase acts directly upon the circulatory system, resulting in an elevation of mean arterial pressure and central venous pressure. This measurable physiological change is the direct, downstream consequence of the oncotic mechanism.

Dosage and Administration Information

Administration and Dosage Guidelines

Hemohes is a solution for infusion that must be administered strictly via the intravenous (IV) route only. The dosage, duration, and rate of the infusion are not fixed and must be individualized based on the patient's condition and the severity of blood or plasma loss. The administration is guided by monitoring standard circulatory parameters, such as pulse rate and blood pressure.

Official Procedural Steps

The correct use of this medicine is structured by specific procedural requirements:

Preparation: The solution should be checked to ensure it is clear and that the container is undamaged before administration; the product is intended for infusion without further dilution.
Initial Rate: The first 10–20 mL must be infused very slowly, while the patient is under close observation, to monitor for any immediate reactions.
Maximum Dose: A specific maximum daily dosage must not be exceeded, and the total duration of treatment is limited to a short period, typically 24 hours.
Infusion Rate: The maximum rate of infusion depends on the clinical situation, with a higher rate permitted for managing acute haemorrhagic shock, but the rate must always be adjusted cautiously.

Use-Context Constraints

The administration of Hemohes requires constant monitoring of the patient's fluid balance, serum ionogram, and renal function (serum creatinine) throughout the infusion. Dosing must be adjusted carefully, particularly in vulnerable groups such as the elderly, emphasizing the need for cautious, individualized administration within the established dose limits.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Hemohes

The following summary describes the type of research that has been conducted for Hetastarch (the active ingredient in Hemohes) and how the evidence base has been structured, according to official and peer-reviewed scientific sources. The purpose of this overview is to provide context on the evidence landscape without offering clinical advice or making claims about expected personal outcomes.

1. Review of Evidence in Critical Illness

The evidence for Hetastarch was evaluated in major, large-scale clinical trials focusing on adult patients with severe critical conditions, such as sepsis and septic shock. These rigorous studies often used follow-up periods of up to 90 days.

Research primarily focused on two major clinical outcomes: all-cause mortality (the rate of patient death) and the incidence of Acute Kidney Injury (AKI), which sometimes requires machine support known as Renal Replacement Therapy (RRT).

Major trials described a pattern where the need for RRT was observed more frequently in critically ill patients who received Hetastarch when compared to those receiving crystalloid solutions. Similarly, trials reported measurements of mortality rates that were observed as part of the overall findings in the Hetastarch groups in this specific context.

Regulatory reviews have concluded that the use of Hetastarch in these critically ill populations was associated with these outcomes, which led to revisions of approved use and regulatory restrictions in this setting.

2. Evidence for Fluid Resuscitation in Acute Trauma and Surgery

Research has explored the administration of Hetastarch in adult patients undergoing major surgical procedures and in those addressing significant fluid loss and circulatory instability (hemorrhagic shock) due to severe acute trauma. These investigations included Randomized Controlled Trials (RCTs) and observational studies.

Studies monitored outcomes related to systemic or functional imbalance, such as maintaining stable blood pressure and heart function, and measured the need for blood product transfusions. Findings across different studies were sometimes variable, particularly when evaluating Hetastarch in non-septic resuscitation settings.

3. Research Gaps and What Remains Uncertain

Follow-up durations were limited in many studies, meaning long-term outcomes and effects on specific organ functions, like the kidneys, are not fully established. Furthermore, data for certain groups, such as children (pediatric patients) and older adults with significant pre-existing comorbidities, remain insufficient.

Key Studies & References

Why Are We Still Debating Hydroxyethyl Starch Solutions? High Quality and Volume of Evidence of Harm is Conclusive (Narrative Review summarizing VISEP, CHEST, 6S)

Frequently Asked Questions (FAQ)

Common questions about Hemohes (FAQ)

Q: Why do doctors use Hemohes instead of just saline?

Official regulatory guidance states that this medicine is used for hypovolemia (low blood volume) when volume restoration with crystalloid solutions, like saline, is not deemed sufficient. Hemohes is described as having properties intended to sustain fluid within the blood vessels, as it works as a colloid solution.

Q: Are there any long-term side effects reported with Hemohes?

Safety information indicates that pruritus (itching) may be protracted, meaning it can last for a long time after administration. Regulatory guidance describes that kidney function monitoring is required for up to 90 days following the infusion.

Q: Can older people safely receive Hemohes?

Official constraints describe the need for cautious dose adjustment by the healthcare professional when the product is used in vulnerable groups, including older adults. Studies have indicated that data for older adults with multiple pre-existing health conditions remains insufficient to fully establish safety and effectiveness.

Q: What is the difference between Hemohes and other volume substitutes?

Hemohes is classified as a synthetic colloid solution or plasma volume expander. Hemohes is intended to sustain volume, while crystalloid solutions (like saline) are known to distribute more widely into surrounding body tissues. This is due to Hemohes' molecular structure.

Q: Is Hemohes part of standard emergency room treatment?

Due to established safety risks, regulatory bodies have severely restricted the use of Hemohes. The medicine is only permitted to treat hypovolemia caused by acute blood loss when other solutions are insufficient. It is explicitly contraindicated (must not be used) in critically ill patients, including those with sepsis or burn injuries.

Q: Why do some studies on Hemohes seem to have conflicting results?

Official research summaries describe that findings in the scientific literature have sometimes been variable. This is related to differences in the study populations (e.g., critical illness versus elective surgery) and the specific formulation (type) of hydroxyethyl starch product being examined.

Q: Does Hemohes cause swelling or fluid retention?

Because Hemohes functions as a volume expander that increases fluid in the blood vessels, regulatory documents list specific safety constraints related to fluid volume. It is contraindicated (must not be used) in patients with conditions like volume overload or pulmonary oedema (fluid in the lungs).

Q: How does the concentration of Hemohes affect its use?

The specific formulation of the hydroxyethyl starch polymers, including their molecular weight and concentration, influences how the medicine works. Official documents describe these physical properties as determining the compound's plasma retention (how long it stays in the blood) and its rate of clearance from the body.

Q: Is Hemohes the same as a blood transfusion?

No, Hemohes is a synthetic colloid solution. Official regulatory documents explicitly state that the medicine is not a substitute for whole blood or plasma.

Q: Does Hemohes affect my red blood cells?

The primary effect of the medicine on blood is hemodilution (the dilution of blood components). Clinical studies have examined whether the use of Hemohes impacts the need for a red blood cell transfusion, particularly when compared to using alternative volume solutions.

Q: How quickly does Hemohes start working?

The medicine's main purpose is defined as acute volume replacement for the immediate restoration of circulatory stability. Official procedural steps describe that the first small portion of the infusion is given very slowly while the patient is under close observation.

Q: What are the signs of a serious problem with Hemohes?

Serious adverse effects documented in regulatory sources include allergic reactions and kidney injury. Signs of potential kidney problems include a change in the frequency or amount of urine, or swelling of the hands or legs. These signs are documented symptoms of potential kidney problems.

Q: What should I tell my doctor about before getting Hemohes?

Official contraindications and monitoring requirements indicate that a patient's history of blood clotting, kidney function, liver disease, or severe heart and circulation issues is relevant. These conditions are formally related to the serious risks associated with the medicine and must be assessed before use.

Q: Is Hemohes used for dehydration?

Regulatory guidance states that the medicine is for hypovolemia (low blood volume) caused by acute blood loss. It is explicitly contraindicated for use in patients who are dehydrated.

Q: Are there different strengths or types of Hemohes?

Yes, the active ingredient, Hydroxyethyl Starch, is available in different formulations (types). These formulations vary in physical properties, such as their molecular weight and concentration, which are described in official information as influencing how long the product lasts and how the body clears it.

Q: How is Hemohes different from albumin?

Hemohes is a synthetic colloid solution derived from starch. In contrast, albumin is a colloid solution that is derived from human protein. Studies often compare the effects of both of these types of volume solutions on circulatory factors and blood coagulation.

Q: Are there any food or drink restrictions while receiving Hemohes?

Official regulatory documents, which include sections for drug-drug and drug-food interactions, do not specifically list any food or drink restrictions for patients receiving this medicine.

Q: Can Hemohes interfere with common lab tests?

As a colloid solution, Hemohes can be detected by laboratory instruments. Official information indicates this may potentially interfere with the accurate measurement of some common laboratory blood tests, including certain enzyme measurements and blood components.

Q: How long has Hemohes been used in medicine?

The active ingredient in Hemohes, hydroxyethyl starch (HES), is not a new compound. Reviews of its use in medicine date back to the 1970s, meaning the compound has been studied and used for several decades.

Q: Can I use Hemohes if I have diabetes?

The polymers in Hemohes can be broken down in the body, which may temporarily increase blood glucose levels. Studies have been conducted to evaluate this effect on blood sugar in patients with and without diabetes.

Q: Is Hemohes a prescription-only medicine?

Yes, regulatory agencies classify this medicine as "Rx only." This means it requires a prescription from a licensed practitioner. Administration of the product typically takes place in a hospital setting under the supervision of a healthcare professional.

How should Hemohes be stored and disposed of?

How to Store and Dispose of Hemohes

Hemohes (Hydroxyethyl Starch) must be stored and handled according to the following official regulatory requirements to maintain its stability and integrity.

Storage Conditions

Temperature: Store at a temperature not exceeding 25 C.
Freezing: The product must not be frozen; if accidentally frozen, it must be discarded immediately.
Container Integrity: Keep the solution in its original container and only use it if the solution is clear or slightly opalescent and the container is undamaged.
Child Safety: Store this medicine out of the sight and reach of children.

Disposal and Handling

Partial Use: Any remaining portion of the solution after administration must be discarded and not stored for later use.
Disposal: Unused product and waste material must be disposed of in accordance with local requirements for pharmaceutical waste.

Hemohes